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Abstract
Background: Rivaroxaban could be an attractive alternative to low molecular weight 
heparin for the treatment of cancer‐associated venous thromboembolism (VTE) but 
the safety and effectiveness remain unclear. We examined risk of recurrent VTE and 
major bleeding associated with rivaroxaban treatment of cancer‐associated VTE.
Methods: Through linkage of nationwide Danish registries, we identified all adults 
with cancer‐associated VTE initiating treatment with rivaroxaban, 2012‐2017. We 
estimated rates and absolute risk of the primary outcome of recurrent VTE and major 
bleeding; all‐cause mortality was studied as a secondary outcome.
Results: We identified 8901 patients with cancer‐associated VTE of whom 476 (5.3%) 
redeemed a prescription for rivaroxaban within 30 days of VTE diagnosis (mean age 
71.5 years, 41% females, 57% with pulmonary embolism). Median time from cancer di-
agnosis to rivaroxaban prescription was 31 days (interquartile range 12‐73 days). Most 
frequent cancers were gastrointestinal (26.1%), genitourinary (23.3%), and hematological 
cancer (12.6%). Few had distant metastases (7.1%). At 6 months, recurrent VTE occurred 
in 6.1% (15.1 events per 100 person‐years) with the highest absolute risks for genitouri-
nary cancer (8.1%), gastrointestinal cancer (7.3%), and breast cancer (6.5%). Major bleed-
ing occurred in 1.9% (5.3 events per 100 person‐years), in particular, in genitourinary 
cancer (4.5%) and lung cancer (4.2%). Eighty deaths (17.8%) occurred during follow up.
Conclusion: In this clinical practice setting, rivaroxaban was rarely used for cancer‐as-
sociated VTE. However, among those who received rivaroxaban, the treatment appeared 
safe and effective with rates comparable to previous studies of selected populations.
K E Y W O R D S
anticoagulants, bleeding, cancer, rivaroxaban, venous thromboembolism
1 |  INTRODUCTION
Venous thromboembolism (VTE) is a frequent complication 
in patients with cancer.1 Oral anticoagulant (OAC) treatment 
is vital but also challenging because cancer can be associated 
with a hypercoagulable state, multi medication, invasive pro-
cedures, and increased risk of bleeding. As a consequence, 
both recurrent VTE and bleeding during treatment are more 
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prevalent than in patients without cancer.2 Current clinical 
practice guidelines recommend treatment with low molecular 
weight heparin (LMWH) over vitamin K antagonists (VKA) 
or non‐VKA OAC (NOAC); this recommendation is well‐
demonstrated with strong evidence for at least a 3‐month 
treatment duration (Grade 1A).3-5
For treatment of VTE in patients without cancer, the 
American College of Chest Physicians Evidence‐Based 
Clinical Practice Guidelines for antithrombotic therapy for 
VTE disease recently recommended NOACs including ri-
varoxaban as long‐term anticoagulant treatment (3 months or 
longer).5 The regulatory approval of the factor Xa inhibitor 
rivaroxaban for VTE was based on the EINSTEIN‐DVT and 
the EINSTEIN‐PE phase 3 noninferiority trials.6,7 A pooled 
post‐hoc analysis of these trials indicated that compared with 
VKA, rivaroxaban was effective at reducing recurrent VTE 
and could be used for cancer patients without compromis-
ing safety.8 Recently, the results of the first two head‐to head 
comparisons between edoxaban and rivaroxaban, respec-
tively, and LMWH also indicated that these regimens were 
comparable in terms of safety and effectiveness.9,10
Rivaroxaban could be an attractive alternative to LMWH 
due to the once daily, oral dosing, which obviate the need for 
daily parenteral injections combined with short half‐life and 
lower price. Due to insufficient data examining outcomes in 
rivaroxaban and LMWH in cancer patients, we examined the 
safety and effectiveness of rivaroxaban in a nationwide cohort 
of patients with active cancer and VTE, and compared our 
findings with previous published studies reporting on treatment 
exposure and associated VTE recurrence in cancer patients.
2 |  MATERIAL AND METHODS
2.1 | Setting and data sources
The source population for this cohort study comprised the 
entire population of Denmark encompassing 5.6 million in-
habitants. Denmark has a tax‐funded universal health care 
system, with equal access to hospitals and primary care for 
all residents, and partial reimbursement of the costs of most 
prescribed medications, including OAC treatments. The 
health care system records most contacts with the health sys-
tem, including births, deaths, hospital visits, and prescrip-
tion claims.11 As a result, data on diagnoses and prescription 
claims are compiled in longitudinal national registries allow-
ing a true nationwide population‐based study with no loss to 
follow up. This study was based on linkage of three nation-
wide registries; (a) the National Patient Register,12 including 
information from all inpatient stays and outpatient visits at 
Danish hospitals; (b) the National Prescription Register,13 
which hold data on all prescription purchases by Danish 
residents since 1995; and (c) the Danish Person Registry,14 
which contain data on sex, date of birth, vital, and emigration 
status. These registries were linked using the unique 10‐digit 
personal registration number assigned to each Danish citizen 
at birth and to residents upon immigration.14
2.2 | Ethical considerations
The study was approved by the Danish Data Protection 
Agency (ref. 2015‐57‐0001). Ethical approval is not re-
quired for anonymous register‐based studies in Denmark. 
The data was provided by the Danish Health Data 
Authority.
2.3 | Study population
We used the National Patient Register to identify all adult 
patients aged 18 years and older with active cancer and an 
inpatient or outpatient primary or secondary discharge diag-
nosis of VTE. As emergency room VTE diagnoses have low 
validity (positive predictive value of 31%), we did not con-
sider these diagnoses.15 To ensure sufficient clinical record 
history for treatment and diagnoses, we excluded patients 
who had not been residents of Denmark for at least 1 year 
before the VTE diagnosis. Active cancer was defined as a di-
agnosis of cancer other than basal‐cell carcinoma of the skin, 
within 6 months of the VTE event, any treatment for cancer 
(see Table S1 for codes) within the 6 months, or recurrent 
or metastatic cancer as described previously.8,16 We classi-
fied cancers according to cancer site (breast, gastrointestinal, 
lung including pleura, genitourinary, gynecological, hema-
tological, metastatic cancer, and other cancers) and cancer 
stage according to the TNM (Tumor, Node, Metastasis) clas-
sification categorized as localized, regional spread, distant 
spread, unstaged, and stage not recorded, (Table S2).
Since we focused on outcomes under rivaroxaban ex-
posure, patients were eligible for study inclusion; if they 
claimed any prescription for rivaroxaban within 30 days of 
discharge from the index VTE in the period from January 1, 
2012 (rivaroxaban was introduced to the Danish market for 
recurrent VTE prophylaxis December 9, 2011) to December 
31, 2017 (end of inclusion). We excluded patients with con-
comitant prescriptions for LMWH, warfarin, dabigatran, or 
apixaban within 30 days of the index VTE.
2.4 | Study outcomes and comorbidity
We derived all primary outcomes from discharge diagnoses 
recorded in the National Patient Register (excluding emer-
gency room diagnoses). The primary effectiveness outcome 
was the first recorded episode of recurrent VTE during fol-
low up. Recurrent VTE was defined by a primary inpatient or 
outpatient diagnosis combined with an objectively confirmed 
VTE diagnosis using imaging in order to rule out repeated 
coding of the index event. According to a recent validation 
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study, this ensures a positive predictive value of 82%.17 In 
addition, follow‐up began 10 days after the date of diagnosis 
of the index VTE to avoid repeated coding of the index event. 
The primary safety outcome was major bleeding events re-
corded as intracranial, gastrointestinal, and major bleeding 
in various anatomical positions and reported in total as “any 
bleeding.” Bleeding events were required to be primary in-
patient diagnoses to increase the validity of the coded diag-
nosis. All‐cause death was included as a secondary outcome.
We ascertained comorbidities at baseline according to 
medication claims within the year before the index VTE event 
and/or history of primary or secondary hospital discharge di-
agnoses (excluding emergency room diagnoses) since 1994 
(introduction of ICD‐10 in Denmark). Comorbidity infor-
mation included cardiovascular and metabolic diseases, life-
style‐related diseases, and indicators for surgery (Table S1). 
We further combined covariate information into the Charlson 
Comorbidity Index18 (Table S3).
2.5 | Statistical analysis
Baseline characteristics at the time of index VTE diagnosis 
were described using means and standard deviations for con-
tinuous measures and percentages for categorical measures. 
Patients were followed until the outcome of interest, emigra-
tion, death, or end of study period (March 23, 2018), which-
ever came first. We used time‐to‐event analysis to analyze 
the risk of study outcomes at 6‐month follow‐up.
To enable comparison with other studies, we first calcu-
lated crude incidence rates as the number of events divided 
by person‐time. Then, we used the pseudovalue approach to 
estimate the cumulative incidence within 6‐month follow‐up, 
assuming death as competing risk.19 Allowing for a thorough 
evaluation, the main analysis was supplemented by analy-
ses stratified by cancer site and cancer stage, and anticancer 
treatments within 30 days before the index VTE.
The analyses were performed using Stata/MP, version 15 
(StataCorp) and R version 3.3.3 (The R Foundation).
2.6 | Literature search methods
We searched PubMed Medline using Medical Subject Headings 
(MeSH) and free text to identify and summarize previous ob-
servational studies on the outcomes of rivaroxaban treatment 
in patients with active cancer and VTE. Development of the 
search strategy described in detail in Table S4 was assisted 
by a trained medical librarian. All searches were performed 
at the end of December 2018. The first author reviewed the 
titles and abstracts and removed articles not relevant according 
to the population, intervention (exposure), comparison, and/
or outcome (PICO criteria). The information summarized by 
our review was collected from the remaining articles and prior 
publications cited by these articles.
3 |  RESULTS
3.1 | Nationwide cohort study in Denmark
From January 1, 2012 to December 31, 2017, we identified 
8901 patients aged 18 years or older with active cancer and 
VTE. Of these, 914 redeemed a prescription for rivaroxaban 
at any time following the index VTE; 744 initiated rivaroxa-
ban within the first year and 476 within 30 days after the 
index VTE diagnosis. The final study population comprised 
these 476 patients with mean age 71.5 years (42% females, 
57% with pulmonary embolism) (Figure 1, Figure S1). Only 
10 patients were diagnosed in 2012; the majority of patients 
was diagnosed in the latter part of the study period (Table 
1). Median time from last cancer diagnosis to prescription 
redemption of rivaroxaban was 31 days (interquartile range, 
IQR, 12‐73 days); median time from the date of last antican-
cer treatment to prescription redemption was 67 days (IQR 
28‐184 days) (Table 1). Forty‐nine patients (10.3%) had a 
previous VTE before cancer diagnosis and 8.2% were prior 
users of OACs. The most frequent cancer type was gastro-
intestinal cancer (26.1%) followed by genitourinary (23.3%) 
and hematological cancer (12.6%) (Table 1). Among the 406 
patients with solid tumors, except for brain cancer, 7.1% had 
distant metastases. Cancer stage was unknown in 54.9% 
F I G U R E  1  Flow chart of the study population
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T A B L E  1  Patient characteristics
Characteristic % (n)
N 476
Study year
2012 2.1 (10)
2013 13.0 (62)
2014 15.8 (75)
2015 19.7 (94)
2016 25.4 (121)
2017 23.9 (114)
Female 42.0 (200)
Mean age (SD) 71.5 (10.8)
Cancer‐related characteristics
Median time from last cancer diagnosis to first rivaroxaban prescription, days (IQR) 31.0 (12.0‐73.0)
Median time from last anticancer treatment to first rivaroxaban prescription, days (IQR) 66.5 (28.0‐184.0)
Any anticancer treatment with 30 d before VTE 21.6 (103)
Radiotherapy 5.9 (28)
Chemotherapy 15.5 (74)
Immune modulating, hormone or biological treatment 7.1 (34)
Cancer site
Breast cancer 9.7 (46)
Gastrointestinal cancer 26.1 (124)
Lung cancer 10.1 (48)
Genitourinary cancer 23.3 (111)
Gynecological cancer 6.1 (29)
Hematological cancer 12.6 (60)
Metastatic cancer 2.1 (10)
Other cancer sites 10.1 (48)
Cancer stage for solid tumors except brain cancera
Localized 16.3 (66)
Regional 14.8 (60)
Distant 7.1 (29)
Unstaged 54.9 (223)
Stage not recorded 6.9 (28)
Medical history
Prior VTE 10.3 (49)
Atrial fibrillation 8.4 (40)
Major surgery within 3 mo 36.8 (175)
Renal dysfunction 5.7 (27)
Alcohol‐related disease 5.3 (25)
Pneumonia within 3 mo 13.0 (62)
Vascular disease 11.1 (53)
Diabetes 12.8 (61)
Prior bleeding 14.3 (68)
Heart failure 10.1 (48)
Prior stroke 10.5 (50)
(Continues)
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patients and not registered in 6.9%. Approximately one‐fifth 
(21.6%) had received anticancer treatment within 30 days 
before, in particular chemotherapy (15.5%) (Table 1).
Figure 2 displays cumulative incidence curves for recurrent 
VTE and major bleeding. As appears, most events occurred 
shortly after the index event. During 6 months follow‐up, 28 
recurrent VTE events occurred (absolute risk 6.1%, rate of 
15.1 events per 100 person‐years) with the highest absolute 
risk in patients with genitourinary cancer (8.1%), gastrointes-
tinal cancer (7.3%), breast cancer (6.5%), and regional cancer 
stage (8.2%). Nine major bleed were diagnosed (absolute risk 
1.9%, rate of 4.7 events per 100 person‐years), in particular, in 
genitourinary cancer (4.5%), lung cancer (4.2%), and patients 
with missing cancer stage (3.6%). Restriction to patients who 
received any anticancer treatment had little impact on the es-
timates (8.8% had a recurrent VTE, 1.0% experienced major 
bleeding). Among patients with chemotherapy treatment cor-
responding estimates were 6.8% and 1.4%, respectively.
Eighty deaths (17.8%) were occurred during 6 months 
follow‐up, equivalent to a rate of 40.6 events per 100 
person‐years.
3.2 | Literature review of previous 
observational studies
Our initial search yielded 151 studies, of which 24 full‐text 
articles were retrieved and assessed for eligibility. After fur-
ther exclusion of 11 studies, our review included 13 cohort 
studies (Figure 3). Study populations ranged from 41 cancer 
patients to 949, with 5 of the 12 studies including less than 100 
patients. Two studies were restricted to patients with catheter‐
related thrombosis and one study included only women with 
gynecological cancer. Duration of follow‐up varied across 
studies from 3 months to a mean follow‐up of 1.36 years. A 
detailed description of the studies is provided in Table S5.
Table 2 presents the absolute risk of VTE recurrence and 
major bleeding for our study compared with estimates re-
trieved by our review. The risk of recurrent VTE ranged from 
0% to 13.2% with the most extreme estimates observed in 
studies including very few patients or not accounting compet-
ing risk of death leading to overestimation of event rates20,21; 
in the majority of studies recurrence risk was approximately 
3%‐5%. The risk of major bleeding ranged from 0% to 17%, 
again with the most extreme estimates obtained in studies 
with very few patients, for example the estimate of a 17% 
risk of major bleeding originated from studies with 18 and 
48 patients, respectively.22,23 Six studies provided estimates 
of clinically relevant nonmajor bleeding, which ranged from 
1.2% to 12.2% (5 events) (Table 2; Table S4). In addition to 
our study, eight studies provided data on all‐cause mortality 
which varied widely from 0.8% to 31.4% (Table 2).
4 |  DISCUSSION
The findings of this nationwide cohort study of patients with 
active cancer and VTE indicate that use of rivaroxaban were 
safe and effective. The VTE recurrence rate of 6.1% and 1.9% 
major bleeds at 6 months follow‐up are in line with the esti-
mates demonstrated by our review of previous cohort studies. 
Our findings also reveal that rivaroxaban was used infre-
quently in Danish cancer patients and presumably mostly for 
selected cancer patients. However, rivaroxaban was increas-
ingly used during the study period.
Characteristic % (n)
Chronic pulmonary disease 18.7 (89)
Myocardial infarction 4.6 (22)
Mean Charlson comorbidity index score (SD) 2.6 (2.4)
Concomitant drugs
Prior oral anticoagulants 8.2 (39)
Systemic corticosteroids 18.7 (89)
Clopidogrel 5.9 (28)
Aspirin 22.1 (105)
Renin‐angiotensin inhibitor 35.7 (170)
NSAID 27.5 (131)
Statins 29.8 (142)
Loop diuretics 17.0 (81)
Non‐loop diuretics 28.6 (136)
Calcium channel blocker 18.9 (90)
SD; standard deviation, IQR, interquartile range; NSAID; nonsteroidal anti‐inflammatory drugs.
a406 patients had solid tumors except brain cancer 
T A B L E  1  (Continued)
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4.1 | Comparison with other studies
In 2014, rivaroxaban was prescribed in 20% of US patients 
with cancer despite lack of evidence and guideline recom-
mendations to support this treatment.24 Sub‐group analy-
ses of patients with cancer from large pivotal phase 3 trials 
have suggested that NOACs are noninferior to LMWH.8,25 
Yet, none of these trials were dedicated to cancer patients 
and less than 5% of the original trial populations had cancer. 
Considering that cancer patients typically represent 20% of 
all patients with VTE in the community, the included trial 
patients likely represent a highly selected subset of cancer pa-
tients encountered in routine clinical care. Nonetheless, based 
on available post‐hoc analyses of these RCTs and meta‐anal-
yses, the updated International Initiative on Thrombosis and 
Cancer (ITAC‐CME) consensus statement recommendations 
from 2016 are that NOACs can be considered for VTE treat-
ment of patients with stable cancer not receiving systemic 
anticancer therapy, and in cases where VKA is an acceptable, 
but not available, treatment choice.3
In 2017, results of the first two head‐to head comparisons 
between LMWH and NOAC for the initial and long‐term 
treatment of VTE in patients with cancer were presented.9,10 
The Hokusai VTE cancer trial randomized 1050 cancer 
patients with acute VTE to edoxaban or LMWH.9 Over 
12 months of therapy, recurrent VTE developed in 7.9% in 
F I G U R E  2  Cumulative risk of recurrent venous thromboembolism (VTE) and major bleeding for 6 months of follow‐up
F I G U R E  3  Flow diagram depicting the study selection process
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the edoxaban group and in 11.3% in the LMWH group; major 
bleeding complications occurred in 6.9% vs 4.0%. The excess 
bleeding events in the edoxaban group were mainly driven by 
upper gastrointestinal bleeds in patients with gastrointestinal 
cancer. The 2‐phase pilot trial SELECT‐D, which random-
ized 406 cancer patients to rivaroxaban and LMWH reported 
a 6 months recurrence rate of 4% in the rivaroxaban group 
and 11% in LMWH group; rates of major bleeding were 4% 
vs 3%, and there were substantially more clinically relevant 
nonmajor bleeds with rivaroxaban than LMWH (13% vs 
2%).10 Several other trials are ongoing.3
Limited data are available on the selection and uses of 
rivaroxaban in clinical practice outside clinical trials, and it 
is debatable whether results from carefully selected trial pop-
ulations can be extrapolated to routine clinical care. Different 
factors, patient‐related or based on a clinical decision, can af-
fect the preferred treatment. The present study therefore adds 
to the existing knowledge. The risk of recurrent VTE in the 
present study is in line with the estimates of previous trials 
whereas the risk of bleeding was substantially lower and no 
excess bleeding events in gastrointestinal cancers were ob-
served. This indicates that in selected cancer patients with 
VTE encountered in routine care, rivaroxaban may be a safe 
and effective alternative to LMWH. Taken together with the 
findings of our review, cumulative evidence suggests that ri-
varoxaban could be a favorable alternative to LMWH in se-
lected cancer patients. However, the output and insights from 
the ongoing RCTs should confirm our observations before 
strong treatment recommendations can be presented.
Cancer patients with VTE is a heterogeneous and complex 
group of patients. Nonetheless, current practice recommenda-
tions apply to all cancer patients, irrespective of cancer site, 
spread, and anticancer treatments. It is very likely that the bi-
ological and clinical heterogeneity influence thrombogenicity 
and response to treatment. Treatment with LMWH can be bur-
densome for the patients because the treatment requires daily 
subcutaneous injections. The need for once or twice daily in-
jection with LMWH might be acceptable for cancer patients 
but oral alternatives would undoubtedly increase quality of life 
and prevent post‐injection subcutaneous fibrosis.26 In a recent 
cohort study the cumulative 6‐month incidence of LMWH dis-
continuation among patients with cancer‐associated VTE was 
approximately 20%.27 The most common reason for discon-
tinuation was pain at the injection site, followed by injection 
site hematoma and allergic reactions.27 Rivaroxaban is admin-
istered orally once daily and the short half‐life (5‐9 hours)28 
facilitate temporary interruptions for procedures or periods of 
thrombocytopenia. However, despite practical advantages of 
rivaroxaban, the use may be limited by the potential increased 
risk of gastrointestinal bleeding especially in gastrointestinal 
cancers. An antidote to immediately reverse the action in case 
of bleeding has been tested in a phase 3 trial but is not cur-
rently on the market.29 Furthermore, there is a risk of drug 
interactions with anticancer treatments, especially those that 
interacts with P‐glycoprotein and cytochrome P450 3A4.3 
Whether these interactions are clinically important remain 
unclear. In this study, event rates were not notably different 
among patients with recent chemotherapy or other antican-
cer treatments. It is likely that more profound knowledge and 
understanding of various anticoagulant options would allow 
clinicians to individualize management according to primary 
tumor site, anticancer treatment, concomitant medications, 
and interventions and thereby enhance patient outcomes and 
quality of care.
4.2 | Strengths and limitations
Strengths of this study include data from a nationwide real‐
world population with access to free health care, which is 
not subject to the selection biases that could affect the previ-
ous observational studies that included only subsets of can-
cer patients. All data were collected prospectively within the 
nationwide registries, which have full coverage for hospital 
admissions, outpatient care visits, and filled prescriptions 
with no patients lost for follow‐up.
This study also has limitations. The lack of a compar-
ison group limits the interpretation of our results. We had 
no data on in‐hospital treatments; therefore, we were unable 
to identify a cohort of LMWH users since in Denmark, this 
treatment in cancer patients is generally administered by 
the hospitals and not recorded in the prescription database. 
Using VKA users as comparisons are problematic because 
this treatment is not the guideline recommended treatment 
and has been demonstrated as less effective than LMWH in 
cancer patients despite maintenance of INR within therapeu-
tic range.30 Another limitation is our reliance on prescription 
purchase as proxy for medication usage, since patients might 
not take their anticoagulant drug.
5 |  CONCLUSION
In conclusion, this nationwide cohort study revealed that 
rivaroxaban was rarely but increasingly used to treat VTE 
in patients with active cancer in routine clinical practice in 
Denmark. In patients selected to this treatment, rivaroxa-
ban appeared safe and effective with rates comparable to 
what has been reported in randomized trials and in minor 
observational studies based on selected patient populations. 
Additional studies are needed to delineate what types of can-
cer patients that might benefit from NOAC treatment.
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